Peregrine Pharmaceuticals Presents Promising Phase I Data At ASCO And Provides Clinic
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) announced that results from a Phase I clinical trial of its lead anti-phosphatidylserine (anti-PS) antibody bavituximab in combination with chemotherapy in patients with advanced cancer were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. The Phase I data indicated that half of evaluable patients in the trial achieved objective tumor response or stable disease after eight weeks of dosing.
More... |
All times are GMT -7. The time now is 07:32 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021